Chinese innovation in cardiovascular drug discovery

British Journal of Pharmacology

Volumn 172, Issue 23, 2015, Pages 5425-5429

  Wang, Xin ^a   Ji, Yong ^b   Yang, Baofeng ^c  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b NANJING MEDICAL UNIVERSITY   (China)

^c HARBIN MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALDOSTERONE ANTAGONIST; BONE MORPHOGENETIC PROTEIN 4; CARDIOVASCULAR AGENT; EPITHELIAL SODIUM CHANNEL; G PROTEIN COUPLED RECEPTOR; HYDROGEN SULFIDE; INTERFERON REGULATORY FACTOR;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CAUSE OF DEATH; CEREBROVASCULAR ACCIDENT; CORONARY ARTERY ATHEROSCLEROSIS; DRUG EFFECT; DRUG RESEARCH; DRUG SAFETY; HEART FAILURE; HEART INFARCTION; HEART VENTRICLE ARRHYTHMIA; HEART VENTRICLE HYPERTROPHY; HUMAN; PREVALENCE; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; SIGNAL TRANSDUCTION; VASCULAR DISEASE; CARDIOVASCULAR DISEASES; CHINA; DRUG DEVELOPMENT;

CARDIOVASCULAR AGENTS; CARDIOVASCULAR DISEASES; CHINA; DRUG DISCOVERY; HUMANS;

EID: 84949497298     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.13363     Document Type: Review

References (39)

1. Alexander SPH, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Spedding M, et al. (2013a). The Concise Guide to PHARMACOLOGY 2013/14: G protein-coupled receptors. Br J Pharmacol 170: 1459-1581.
2. Alexander SPH, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Spedding M, et al. (2013b). The Concise Guide to PHARMACOLOGY 2013/14: ligand-gated ion channels. Br J Pharmacol 170: 1582-1606.
3. Alexander SPH, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Catterall WA, et al. (2013c). The concise guide to pharmacology 2013/14: ion channels. Br J Pharmacol 170: 1607-1651.
4. Alexander SPH, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Spedding M, et al. (2013d). The Concise Guide to PHARMACOLOGY 2013/14: nuclear hormone receptors. Br J Pharmacol 170: 1652-1675.
5. Alexander SPH, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Spedding M, et al. (2013e). The Concise Guide to PHARMACOLOGY 2013/14: catalytic receptors. Br J Pharmacol 170: 1676-1705.
6. Alexander SPH, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Spedding M, et al. (2013f). The concise guide to PHARMACOLOGY 2013/14: enzymes. Br J Pharmacol 170: 1797-1867.
7. Ben J, Zhu X, Zhang H, Chen Q, (2015). Class A1 scavenger receptors in cardiovascular diseases. Br J Pharmacol 172: 5435-5443. doi: 10.1111/bph.13105
8. Brunner H, Cockcroft JR, Deanfield J, Donald A, Ferrannini E, Halcox J, et al. (2005). Endothelial function and dysfunction. Part II: association with cardiovascular risk factors and diseases. A statement by the Working Group on Endothelins and Endothelial Factors of the European Society of Hypertension. J Hypertens 23: 233-246.
9. Cheang WS, Tian XY, Wong WT, Huang Y, (2015). The peroxisome proliferator-activated receptors in cardiovascular diseases: experimental benefits and clinical challenges. Br J Pharmacol 172: 5512-5522. doi: 10.1111/bph.13029
10. Cheng WL, Wang PX, Wang T, Zhang Y, Du C, Li H, et al. (2015). Regulator of G-protein signalling 5 protects against atherosclerosis in apolipoprotein E-deficient mice. Br J Pharmacol 172: 5676-5689. doi: 10.1111/bph.12991
11. Floyd CN, Ferro A, (2014). Mechanisms of aspirin resistance. Pharmacol Ther 141: 69-78.
12. Frey N, Olson EN, (2003). Cardiac hypertrophy: the good, the bad, and the ugly. Annu Rev Physiol 65: 45-79.
13. Gao F, Sun RJ, Ji Y, Yang BF, (2015). Cardiovascular research is thriving in China. Br J Pharmacol 172: 5430-5434. doi: 10.1111/bph.12826
14. Gong Y, Lin M, Piao L, Li X, Yang F, Zhang J, et al. (2015). Aspirin enhances protective effect of fish oil against thrombosis and injury-induced vascular remodelling. Br J Pharmacol 172: 5647-5660. doi: 10.1111/bph.12986
15. Gouya G, Arrich J, Wolzt M, Huber K, Verheugt FW, Gurbel PA, et al. (2014). Antiplatelet treatment for prevention of cerebrovascular events in patients with vascular diseases: a systematic review and meta-analysis. Stroke 45: 492-503.
16. He X, Zhao M, Bi X, Sun L, Yu X, Zhao M, et al. (2015). Novel strategies and underlying protective mechanisms of modulation of vagal activity in cardiovascular diseases. Br J Pharmacol 172: 5489-5500. doi: 10.1111/bph.13010
17. Heidenreich PA, Albert NM, Allen LA, Bluemke DA, Butler J, Fonarow GC, et al. (2013). Forecasting the impact of heart failure in the United States: a policy statement from the American Heart Association. Circ Heart Fail 6: 606-619.
18. Kemp CD, Conte JV, (2012). The pathophysiology of heart failure. Cardiovasc Pathol 21: 365-371.
19. Lang H, Li Q, Yu H, Li P, Lu Z, Xiong S, et al. (2015). Activation of TRPV1 attenuates high salt-induced cardiac hypertrophy through improvement of mitochondrial function. Br J Pharmacol 172: 5548-5558. doi: 10.1111/bph.12987
20. Libby P, Lichtman AH, Hansson GK, (2013). Immune effector mechanisms implicated in atherosclerosis: from mice to humans. Immunity 38: 1092-1104.
21. Liu HB, Zhang J, Sun YY, Li XY, Jiang S, Liu MY, et al. (2015a). Dietary salt regulates epithelial sodium channels in rat endothelial cells: adaptation of vasculature to salt. Br J Pharmacol 172: 5634-5646. doi: 10.1111/bph.13185
22. Liu Z, Xu S, Huang X, Wang J, Gao S, Li H, et al. (2015b). Cryptotanshinone, an orally bioactive herbal compound from Danshen, attenuates atherosclerosis in apolipoprotein E-deficient mice: role of lectin-like oxidized LDL receptor-1 (LOX-1). Br J Pharmacol 172: 5661-5675. doi: 10.1111/bph.13068
23. 2+/calmodulin-dependent protein kinase II pathway. Br J Pharmacol 172: 5619-5633. doi: 10.1111/bph.13183
24. Lv Y, Bai S, Zhang H, Zhang H, Meng J, Li L, et al. (2015). Aldosterone down-regulates the slowly activated delayed rectifier potassium current in adult guinea pig cardiomyocytes. Br J Pharmacol 172: 5596-5608. doi: 10.1111/bph.13163
25. Marangoni F, Poli A, (2013). Clinical pharmacology of n-3 polyunsaturated fatty acids: non-lipidic metabolic and hemodynamic effects in human patients. Atheroscler Suppl 14: 230-236.
26. Meng G, Ma Y, Xie L, Ferro A, Ji Y, (2015). Emerging role of hydrogen sulfide in hypertension and related cardiovascular diseases. Br J Pharmacol 172: 5501-5511. doi: 10.1111/bph.12900
27. Miyamoto M, Fujita T, Kimura Y, Maruyama M, Harada H, Sudo Y, et al. (1988). Regulated expression of a gene encoding a nuclear factor, IRF-1, that specifically binds to IFN-beta gene regulatory elements. Cell 54: 903-913.
28. Olshansky B, Sabbah HN, Hauptman PJ, Colucci WS, (2008). Parasympathetic nervous system and heart failure: pathophysiology and potential implications for therapy. Circulation 118: 863-871.
29. Pan ZW, Lu YJ, Yang BF, (2015). Advances in exploring the role of microRNAs in the pathogenesis, diagnosis and therapy of cardiac diseases in China. Br J Pharmacol 172: 5435-5443. doi: 10.1111/bph.13015
30. Pawson AJ, Sharman JL, Benson HE, Faccenda E, Alexander SP, Buneman OP, et al.; NC-IUPHAR. (2014). The IUPHAR/BPS Guide to PHARMACOLOGY: an expert-driven knowledgebase of drug targets and their ligands. Nucl Acids Res 42 (Database Issue): D1098-D1106.
31. Qin W, Du N, Zhang L, Wu X, Hu Y, Li X, et al. (2015). Genistein alleviates pressure overload-induced cardiac dysfunction and interstitial fibrosis in mice. Br J Pharmacol 172: 5559-5572. doi: 10.1111/bph.13002
32. Wang X, Cheang WS, Yang H, Xiao L, Lai B, Zhang M, et al. (2015a). Nuciferine relaxes rat mesenteric arteries through endothelium-dependent and -independent mechanisms. Br J Pharmacol 172: 5609-5618. doi: 10.1111/bph.13021
33. Wang YC, Xiao XL, Li N, Yang D, Xing Y, Huo R, et al. (2015b). Oestrogen inhibits BMP4-induced BMP4 expression in cardiomyocytes: a potential mechanism of oestrogen-mediated protection against cardiac hypertrophy. Br J Pharmacol 172: 5586-5595. doi: 10.1111/bph.12983
34. 2-adrenoceptor signalling in heart failure: pathophysiology and drug discovery. Br J Pharmacol 172: 5444-5456. doi: 10.1111/bph.12965
35. 2-adrenoceptor. Br J Pharmacol 172: 5477-5488. doi: 10.1111/bph.13049
36. Yin Q, Lu H, Bai Y, Tian A, Yang Q, Wu J, et al. (2015). A metabolite of Danshen formulae attenuates cardiac fibrosis induced by isoprenaline, via a NOX2/ROS/p38 pathway. Br J Pharmacol 172: 5573-5585. doi: 10.1111/bph.13133
37. Yuan Y, Bai X, Luo C, Wang K, Zhang H, (2015). The virtual heart as a platform for screening drug cardiotoxicity. Br J Pharmacol 172: 5531-5547. doi: 10.1111/bph.12996
38. Zhang XJ, Jiang DS, Li H, (2015). The interferon regulatory factors as novel potential targets in the treatment of cardiovascular diseases. Br J Pharmacol 172: 5457-5476. doi: 10.1111/bph.12881
39. Zhou F, Hao G, Zhang J, Zheng Y, Wu X, Hao K, et al. (2015). Protective effect of 23-hydroxybetulinic acid on doxorubicin-induced cardiotoxicity: a correlation with the inhibition of carbonyl reductase-mediated metabolism. Br J Pharmacol 172: 5690-5703. doi: 10.1111/bph.12995